Infinity Bio Inc – Weekly Recap

Infinity Bio Inc featured prominently this week as it aligned its immune profiling platform with emerging research on immune aging and multi-omic cohort studies. The company highlighted a Nature-backed Human Immune Health Atlas that maps non-linear immune aging, early T cell transcriptional changes, and impaired vaccine responses across adults aged 25–90.

Infinity Bio emphasized how this work introduces an RNA Age Metric that distinguishes biological from chronological immune age and could inform age-tailored vaccines and therapies. The company positioned its Antibody Reactome Profiling as a complementary tool to such cohorts, aiming to map cumulative exposure to self, viral, and environmental antigens and characterize emerging autoimmunity.

By focusing on autoantibody detection and antigen landscape mapping, Infinity Bio underscored the potential to stratify patients by immune age and autoimmune risk in large-scale biomarker programs. This strategy points toward applications in precision immunology, aging-related research, and companion diagnostics, although specific partnerships and monetization timelines were not disclosed.

The company also highlighted its presence at IMMUNOLOGY2026 in Boston, where scientist Katy Shaw-Saliba, Ph.D., presented a poster on decoding the antibody reactome at scale using novel antigen display technology. Infinity Bio maintained a booth presence, with team member Jean-Philippe Laine engaging with researchers, potential partners, and recruits on the exhibition floor.

These conference activities suggest a concerted effort to showcase antibody reactomics capabilities, strengthen academic and industry relationships, and support talent acquisition. Collectively, Infinity Bio’s focus on immune-aging research, cohort-based analytics, and scientific visibility points to a week of strategic brand positioning within the immunology tools and precision medicine ecosystem.